FDA drug‑evaluation chief warns against over‑reliance on placebo effect in trials

The passage provides commentary from a long‑time FDA official about placebo methodology, but offers no concrete allegations, financial flows, or misconduct involving high‑level officials. It is largel Robert Temple, a four‑decade FDA drug‑evaluation veteran, critiques current placebo usage. He suggests three‑arm trial designs to better isolate placebo effects. Temple notes that automatic blood‑pre